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ABSTRACT 
 
Elena V. Kan: Periapical Microsurgery: The Effects of  
Locally Injected Dexamethasone on post-operative Healing 
(Under the direction of Peter Z. Tawil) 
 
 
Substantial inflammation, bruising and pain have been an inevitable consequence of 
oral surgery.  Objectives: To study a protocol to reduce these complications after periapical 
microsurgery. Hypothesis is that a single local submucosal injection of 4.0mg of 
dexamethasone at the time of periapical microsurgery can reduce the postoperative 
complications. Materials and Methods: Sixty patients received injections of either 
dexamethasone or a placebo solution at the conclusion of a standardized periapical 
microsurgery within a double-blind randomized controlled clinical trial.  A self-administered 
survey provided data for analytical comparison. Data was analyzed at a significance level of 
95% using Chi square and the Fisher Exact tests.  Results:  Subjects who received the 
dexamethasone injection reported less swelling 24 hours post-periapical microsurgery 
compared to the placebo at a statistical significant level of greater than 98%.  Conclusion: A 
dexamethasone injection minimizes post-operative swelling 24 hours following periapical 
microsurgery. 
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CHAPTER 1:  INTRODUCTION, STUDY DEVELOPMENT AND ANALYSIS 
Post-treatment complications in endodontics continue to be a significant problem in 
dentistry.  Initial endodontic therapy does not produce an acceptable treatment outcome in 
approximately one-third of all cases and, therefore, endodontic retreatment is required (
Introduction 
1).  
Analysis of surgical and non-surgical retreatment therapies (2) have found that healing rates 
are not substantially different between the two approaches (3).   
Traditionally, the cost of retreatment is higher since treatment typically takes multiple 
appointments.  This is in contrast to a surgical retreatment which can be performed in a single 
appointment.  Furthermore, a traditional retreatment approach requires access through the 
crown and can involve replacing the crown.  This is in contrast to periapical surgery that only 
involves resection of soft tissue, bone and root structure without penetrating the crown 
structure.  In addition, there is a high frequency of flare-ups experienced by patients who are 
treated with the traditional orthograde retreatment of root canal therapy (4).  Periapical 
surgery is a more efficient and less expensive method for retreatment relative to the 
orthograde method which involves removing posts, root canal filling material, and often 
replacing a crown (3, 5).   
Periapical surgery is regarded as an integral part of modern endodontics (6, 7).  
Endodontic surgeries account for approximately 6 to 10% of the typical endodontic practice 
treatments (8, 9) and are considered an extension of non-surgical treatments.  Based on short 
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and long term evaluations, periapical surgeries have a 91 to 97% healing success rate (10, 11) 
making periapical microsurgery a good treatment option.   
Research indicates that inflammation, pain, swelling, and bruising have long been an 
inevitable consequence of oral surgery (5).  The same research indicates that post-endodontic 
surgical discomfort can cause 23% of patients to miss work (5).  Some studies have found that 
patients with pre-operative endodontic pain will continue to have post-treatment pain in up to 
80% of the cases (12-14).  The greatest concern among endodontic surgery patients is 
experiencing pain (10).  According to one study, patients experience their peak pain by the 
end of the day of their endodontic surgery (5). Although all patients endure some level of 
pain, approximately two-thirds of the patients that undergo endodontic surgery require 
analgesics to lessen their pain (15).  
Pain is a complex process that involves sensory, emotional, and conceptual aspects 
(16).  Post-treatment analgesic intervention is necessary in many endodontic cases to manage 
pain.  There are various classes of drugs that have been proposed in the management of post-
treatment endodontic pain and discomfort.  These classes include NSAIDs, Acetaminophen, 
opioids, and corticosteroids (12, 14, 15, 17).  Research has proposed that corticosteroids are 
effective in treating pain (12, 14). 
The majority of evidence evaluating post-surgical discomfort and complications 
utilizes the oral surgery third molar extraction model and views the aspect of pain as a 
consequence of the acute inflammatory reaction.  However, pain in endodontic origin differs 
from this model in that it is associated with chronic inflammation (18), the presence of 
bacterial by-products, and the activation of inflammatory mediators and immune cells (19).  
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Wound healing or repair after surgical procedures is an important component of inflammation 
(20) and is a necessary physiological response of the body to the injury (21). 
Review of Inflammation 
Inflammation has been defined as “the local reaction of vascularized tissue to injury” 
(22).  Manipulation of the soft and hard tissues during endodontic surgery leads to an 
inflammatory cascade via biological mediators (e.g. prostaglandins, leukotrienes, bradykinins, 
histamine, serotonin, and others) that are released from blood vessels and cells in the injured 
area (22) and serve a specific role at each stage of the inflammatory process (20).  This 
inflammatory cascade results in pain and vasodilation which leads later to edema and 
hematoma in the injured area (21).   
Inflammation can be divided into three stages: acute, chronic, and repair with no clear 
dividing line among them (20, 23).  Periapical microsurgery involves all three stages: chronic 
inflammation due to the periapical lesion that is present at the time of treatment, acute 
inflammation at the time of hard and soft tissue manipulation, and repair after conclusion of 
the surgical intervention.   
Acute inflammation is characterized by the transudation of leukocytes into the tissue, 
whereas chronic inflammation features the presence of leukocytes in the tissues (23).  Acute 
inflammation is an exudative process where small vessels become permeable.  This allows 
plasma proteins and fluid to leave the bloodstream and enter the tissue to form a loose 
network of fluid, fibrin, and white blood cells (20).  Chronic inflammation, on the other hand, 
is a proliferative process with the presence of fibroblasts and angioblasts (20) and nerve 
sprouting (24).  Acute inflammation involves an influx of neutrophils, while chronic 
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inflammation involves mononuclear inflammatory cells, such as macrophages, lymphocytes, 
and plasma cells (23, 24).   
The first event in any inflammatory reaction is tissue injury.  After the initial injury, a 
transient vasoconstriction occurs and is followed by vasodilation of the tissue.  The injured 
tissue becomes painful, hot, erythematous, and edematous (20, 21).  There are many 
biochemical mediators that take place to contribute to the symptoms and signs of 
inflammation.   
Arachidonic acid is a major precursor of inflammatory reaction and its metabolites are 
important mediators in the inflammatory cascade (Figure 1).  Major arachidonic acid 
derivatives include prostaglandins and leukotrienes.  Both prostaglandins and leukotrienes are 
responsible for delaying and prolonging stages in vascular permeability.  They are long-chain, 
lipid-soluble fatty acids that are present in all tissues and are formed within seconds after 
various stimuli.  In inflammation, macrophages and neutrophiles are responsible for the 
production of both prostaglandins and leukotrienes.  Arachidonic acid serves as the precursor 
to both prostaglandins and leukotrienes and is produced by the action of phospholipase A2.  
Phospholipase A2 is an enzyme that is found in all human cells. 
The oxidation of phospholipase A2 leads to the formation of arachidonic acid from 
cell membrane phospholipids.  Once arachidonic acid is formed, it is metabolized by two 
major enzymes: cyclooxygenase or lipoxygenase.   The cyclooxygenase pathway involves 
prostaglandins, which produce vasodilation of tissues and increase of vascular permeability.  
The lipoxygenase pathway involves leukotrienes (21).   
All of the components of inflammatory cascade cause patient discomfort.  
Inflammation is a major cause of pain, swelling and bruising that accompany any surgery.  
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One method to decrease these critical signs of inflammation is through the use of anti-
inflammatory agents.  These agents aid in the reduction of unpleasant side-effects of the 
inflammatory cascade through the inhibition of the steps in the formation of arachidonic acid 
and its metabolites.  The potential for anti-inflammatory agents to prevent pain, swelling, and 
bruising depends on the suppression of the release of the inflammatory mediators.  A decrease 
in the amount of inflammatory mediators present leads to a reduction in vascular permeability.  
This in turn decreases fluid accumulation within tissues, resulting in a decreased tissue 
pressure that translates to less pain, swelling and potential bruising (14). Various medications 
have been used to interfere with inflammation to prevent or stop pain, swelling and/or 
bruising.  Two commonly used classes of medications for this are NSAIDs and 
corticosteroids.   
NSAIDs are cyclooxygenase inhibitors and prevent formation of prostaglandins and 
thromboxanes from arachidonic acid (25), but do not affect the lipoxygenase pathways 
(Figure 2).  In contrast, corticosteroids prevent the release of arachidonic acid which inhibits 
both inflammatory pathways and effectively prevent inflammation (26-28).  As a result, the 
anti-inflammatory efficacy of corticosteroids is more pronounced than NSAIDs, which has led 
to their use after surgical procedures (29-32). 
Many different steroids are currently available on the market.  One of the first clinical 
applications of corticosteroids was the use of compound E, cortisone, compound F, and 
hydrocortisone, in the treatment of rheumatic fever was in the late 1940’s (33).   Past studies 
have primarily focused on the use of glucocorticosteroids (cortisone and hydrocortisone) in 
dental applications.  Dexamethasone is one of the most recent corticosteroids to become 
available on the market.  Dexamethasone has been successful in reducing the post-operative 
5
sequelae (10, 29-32, 34-40) that typically accompanies oral surgery.  The anti-inflammatory 
effect is a result of the suppression of the migration of neutrophils, leukocytes, and 
macrophages through the inhibition of the formation of arachidonic acid, thus blocking the 
cyclo-oxygenase and lipoxygenase pathways and respective synthesis of prostaglandins and 
leukotrienes (41, 42).  Corticosteroids can be delivered through a variety of methods, 
including orally, intravenously (37, 43),  intramuscularly (12, 14, 31), submucosally (36), 
intraligamentary (29, 30, 38, 40, 41, 44), supraperiostealy (45) and intraosseously (46, 47). 
The submucosal injection enables the application of anti-inflammatory agents at a precise site 
to effect a pharmacological action in sufficient quantities.  More importantly, dentists are 
familiar with submucosal injections over other techniques.  
Review of Steroids 
The adrenal cortex synthesizes corticosteroids from cholesterol.  Corticosteroids 
contain 21 carbon atoms in a 4 member hydrocarbon ring.  Adrenal corticosteroids are 
necessary regulators of homeostasis (48).  These corticosteroids are produced naturally and 
include different classes, mineralocorticoid (aldosterone), the sex hormones (testosterone, 
estrogen, progesterone), and glucocorticosteroids (cortisol).  Aldosterone affects the human 
body’s water and electrolyte balance. It is primarily secreted by stimulation of the kidney’s 
renin-angiotensin system.  Therefore, water and electrolyte balance are not affected by 
suppression of adrenal glands (48).  Sex hormones are produced by gonads and adrenal glands 
(48). 
Glucocorticosteroids act on multiple sites to inhibit immune and inflammatory 
reactions.  Cortisol is the primary glucocorticosteroid that is synthesized by the body and is 
secreted by the adrenal cortex.  This process is controlled by the hypothalamus and anterior 
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pituitary glands.  Along with the adrenal cortex, these structures make up the hypothalamic-
pituatatry-adrenal axis.  This system regulates glucorticosteroid synthesis.  The hypothalamus 
produces corticotropin-releasing hormone, which travels to the anterior pituitary gland via the 
hyphothalamic-hypohyseal portal system.  This corticotropin-releasing hormone stimulates 
release of the adrenocorticotropic hormone (ACTH) by the pituitary gland (49).  ACTH is the 
main regulator of cortisol.  The metabolism of corticosteroids occurs in the liver, and later, 
through excretion in the urine (41, 42, 48).   
The chemical modification of cortisol produces a number of synthetic corticosteroids.  
Synthetic corticosteroids, as well as cortisol, are 90% bound to plasma proteins (albumin and 
corticosteroid-binding globulin).  Only a small unbound portion of corticosteroids are free to 
enter the cell and mediate the anti-inflammatory effect at any time.  Although cortisol 
normally has a half-life of 90 minutes, chemical modifications to its composition can cause it 
to have a greater anti-inflammatory effect and an increased duration of action.    
Indications and Contraindications of Steroids 
There are many applications of corticosteroids in dentistry.  Oral surgery studies have 
used dexamethasone for reducing edema, pain, and trismus after extraction of third molars 
utilizing various injection methods (31, 36, 37) and oral formulations (32, 35, 38).  Research 
has demonstrated a pain reduction of 50% when dexamethasone was used pre- and post-
operatively after extraction of 3rd molars (32).  More than 1/3 of patients traditionally require 
post-operative analgesics after surgical extraction of third molars.  Evidence suggests that 8.0 
mg of dexamethasone administered orally significantly reduced post-operative pain (35).   
Early case reports indicated the use of corticosteroids in dentistry for alleviating 
symptoms related to refractory facial and oral lesions with unknown etiology (51).   
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Pre-operative administration of oral dexamethasone in a periodontal surgery model 
finds that it is effective in reducing pain after periodontal surgeries for the initial eight hours 
following treatment (30).  The same author found in another study that it is better to use a 
single oral dose of 8.0 mg of dexamethasone than two doses of 4.0 mg of dexamethasone in 
reducing pain one-hour prior to periodontal surgery (29).  Patient compliance and the need for 
repeated doses to sustain adequate steroid concentration can become problematic with oral 
administration.  It is more predictable and effective to inject the dexamethasone at the time of 
the surgery rather than using the oral route. 
An animal study showed that the supraperiosteal infiltration of dexamethasone into the 
submucosal tissue had a significant anti-inflammatory effect on the injured periapical tissues 
(61).  The study also stressed the importance of patient compliance and use of an infiltration 
method instead of oral administration.  Submucosal deposition of dexamethasone is the 
preferred method of delivery, as an application at the site of inflammation provides the 
maximum anti-inflammatory effect on tissues.  Intramuscular administration has been shown 
to have the same effect as oral infiltration (14).  However, a practitioner should be 
experienced in giving an intramuscular injection as accuracy is paramount.  The oral 
infiltration injection is a familiar procedure in dentistry.  Another animal study found similar 
effects of dexamethasone that was deposited and absorbed in the maxilla and mandible (62).  
This finding can be used to prevent flare-ups after endodontic treatment and periapical 
microsurgery using similar doses for the maxilla and/or mandible.   
Studies have demonstrated that corticosteroids can prolong pulpal anesthesia with 
inferior alveolar nerve blocks in patients that experience the painful condition of irreversible 
pulpitis (53).  However, one study showed that an intrasulcular injection of ketorolac is very 
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painful and not recommended as a supplemental treatment in patients with irreversible pulpitis 
(54).   
Corticosteroids have been an effective treatment for the injured and/or compressed 
inferior alveolar nerve after the extrusion of root canal filling materials (55).   
There are documented cases of corticosteroids being used in instances of sodium 
hypochlorite incidents with or without neurological deficit during endodontic procedures (56, 
57), thus, promoting recovery. 
In some instances, placing corticosteroids locally into the root canal space prevents 
and possibly treats flare-ups after endodontic treatments (17, 52, 58-60).   
Supra-periosteal infiltration with a single dose of 4.0 mg of dexamethasone has been 
found to be effective in reducing acute pain after endodontic treatment if administered within 
the first 24 hours, but not more than 48 hours (45).  Most endodontic patients with acute pain 
experience pain even after endodontic treatment had been performed (5, 58).   
Some endodontic microsurgery protocols incorporate oral dexamethasone to be 
administered preoperatively and postoperatively (34, 39, 40).  One endodontic surgical model 
suggested that the routine use of oral dexamethasone is a safe method to reduce pain and 
swelling after endodontic surgery (10).   
Corticosteroids at higher levels with multiple dosages have been found to cause 
adrenal fatigue and can mask symptoms of bacterial infection (48, 49).  One study showed 
that a one-week course of corticosteroids is not harmful, but instead, very effective in 
reducing post-surgical dental pain and swelling (15).  The important aspect of this study was 
that patients required less NSAIDs and opioids to control pain.  A single dose of 
corticosteroids has been proven to be safe and effective in terms of reducing pain and swelling 
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(39).  One of the earlier studies concluded that a single large intravenous dose of 
dexamethasone (2.0 milligrams per kilogram of body weight) does not have any harmful side 
effects (43).   
Some studies raised concerns regarding expanded uses of corticosteroids in dentistry 
due to their adverse reactions.  These studies concluded that corticosteroids can cause 
psychosis, memory disturbances, and hallucinations (63-65).  These case documented reports 
are based upon small doses that patients were taking for prolonged periods of time. Patients 
who suffer from mental illnesses, pregnant woman, immune-compromised patients (i.e. 
Cushing’s syndrome, tuberculosis, systemic fungal infection, uncontrolled diabetes), chronic 
pain patients, or patients with hyperthyroidism should not take systemic corticosteroids for a 
prolonged period of time (48, 66-69).  Based on the above, this study’s small single dose of 
corticosteroids at the conclusion of the periapical microsurgery is safe, effective and efficient 
in reducing post-operative complications. 
 
10
Determining the sample size for a research survey is the task of choosing the number of 
observations or patients to include in the statistical sample.  The goal of this study was to make 
statistical inferences about the population from the sample.  As with any empirical study, the 
sample size was of paramount importance.  In some 
Study Development 
Sample Size 
experimental designs, where a study may 
be divided into different treatment groups, there may be different sample sizes for each group.  
In this case, for the sake of statistical tests and administrative ease, the same number of patients 
were placed in each group. 
The statistical power of a sample size relies on many subjective estimates.  There has 
been little endodontic research in this specific area.  Therefore, there was no specific proxy as to 
expected variance or sample size.  The only guidance was based upon anecdotal evidence from 
oral surgeons’ experience with an injection-form of dexamethasone. 
After balancing the statistical methods to be employed, costs, and timeline, it was 
estimated that the sample size of sixty patients (n = 60) would provide the necessary statistical 
significance to make valid conclusions.  Patients were selected from those that were currently or 
previously recommended for endodontic periapical microsurgery by the UNC Dental School 
Endodontic Department.  Participants were randomly placed into two groups by UNC 
Investigational Drug Services (IDS).  The first group of participants, which totaled thirty (x = 
30), received an injection of 4.0 mg of dexamethasone solution.  The second group of 
participants, which also totaled thirty (y = 30), received an injection of placebo saline solution.  
The formula for the sample population is as follows: 
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   n  =  x  +  y 
Where, 
x = Number of dexamethasone group patients 
y = Number of placebo group patients 
n = Total population of the sample 
Patient Selection 
This study involved sixty (n = 60) patients that were prequalified and selected for 
endodontic periapical microsurgery from the UNC Dental School Endodontic Department’s 
patient files.  This study included the first sixty qualified patients on a first-come-first-served 
basis that agreed to participate.  Current patients that would likely qualify were considered 
immediately.  Endodontic residents in the department were aware of the research and alerted the 
patient and the principal investigator of a potential case.  Clinical and radiographic exams were 
used to determine patient qualifications.  The selection process sought males or females of at 
least eighteen years of age.  Patients were required to be in relatively good health with no 
significant medical conditions.   
All root canal treated cases with apical periodontitis were eligible for inclusion where 
previously endodontically treated teeth had non-healing lesions, endodontic retreatment was 
impossible (post, anatomy), or cases with a high possibility of failure after a traditional root 
canal treatment.  All teeth groups (anterior, premolars, molars, maxillary or mandibular teeth) 
were eligible for the study.   
Patients that were pregnant, immune-compromised or suffering from chronic pain were 
removed from consideration.  Patients taking systemic corticosteroids were excluded from the 
list of candidates.  If the patients displayed acute symptoms, acute apical abscess, Miller class II 
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or III mobility, horizontal/vertical root fractures, combined endodontic-periodontal lesions, 
compromised crown-to-root ratio or patients with systemic conditions were removed from 
consideration. 
Written and verbal informed consents were obtained from qualified participants.  
Among much other information, patients were informed that they may or may not actually 
receive the drug dexamethasone.  Patients were informed that they might actually receive a 
placebo.  Given the nature and importance of these communications and the survey, those not 
literate in English were removed from consideration. 
Criteria and Restrictions 
Patients were subject to certain study criteria and restrictions with the aim of upholding 
the validity of the study while maintaining a safe procedure for patients.  As with most clinical 
studies, one goal of the criteria and restrictions is to create a uniform environment.  The study 
boundaries can be used to isolate the event to be studied from the influence of other factors.  
This provides the truest cause-and-effect result. 
Clinical and radiographic examinations as well as a medical history review were used to 
determine whether a potential candidate’s qualifications adhered to the criteria and restrictions. 
Another goal of the study conditions is to maintain patient health and safety.  The study 
submitted to the stringent conditions and restrictions place upon it by the IDS and IRB.  Patient 
candidates whose physical qualities might overshadow the study results were removed from 
consideration.  Disqualification was also done in some instances out of consideration of the 
candidate’s health and safety.   
The selection process sought males or females of at least eighteen years of age.  This 
created a pool of individuals above the age of consent.  This avoided exposing minors to any 
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unforeseen risks of the study. 
Candidates were questioned pre-operatively about their health and medications that they 
were taking.  As all candidates were current patients at the UNC Dental School, merely 
updating their records was the primary task.  As current patients, this provided a preliminary 
screening of that patient’s vital readings (blood pressure and pulse) to ensure they were within 
safety standards as set in the IDS and IRB as well as the school’s standards.  Candidates that 
were pregnant were removed from consideration.  Although the drug dosage was small and 
local, pregnant candidates were removed from the selection out of an abundance of caution for 
the fetus.  Females of child-bearing age were offered a pregnancy test to determine if they were 
pregnant.  Every female patient was required to give verbal confirmation that she was not 
pregnant or planning to become pregnant prior to inclusion in the study. 
Surgical Procedure 
All research and surgical consents were filled out by the participants prior to the 
surgical procedures.  With the exception of the incisions and suturing, all microsurgical 
procedures were performed using a Surgical Operating Microscope (Global G6 Microscope, 
Global Surgical Corporation, St. Louis, MO).  All surgeries were performed using modern 
microsurgical techniques (70, 71).  All participants were required to rinse their mouth with 
0.12 % chlorhexidinegluconate rinse (Peridex 3M ESPE) for one minute immediately prior to 
the periapical microsurgery.  Chlorhexidine mouth rinse plays an important role in pre-
disinfection of the surgical area.  About 30% of chlorhexidine may be retained in the mouth 
after rinsing for one minute (72) and once bound to the oral tissues, chlorhexidine can be 
released for up to 12 hours for a prolonged bacteriocidal effect (72, 73).  
Local anesthesia with 2% lidocaine and 1:100,000 of epinephrine was administered in 
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the area of the surgery via local infiltration.  In addition, a 2% lidocaine solution with 
1:50,000 of epinephrine was administered in the planned incision area in order to achieve 
improved hemostasis.  Local anesthesia serves two purposes: to prevent pain during surgery 
and to minimize surgical hemorrhage due to vasoconstriction.  A 2% lidocaine solution with 
epinephrine is the anesthetic of choice since it activates alpha receptors that are present in the 
muscles of the arterioles, periodontium, and submucosa causing vasoconstriction (74, 75). 
After anesthesia, a #15C surgical blade was used to make papilla-base incisions and 
vertical releasing incisions to allow adequate access to the surgical area (76, 77).  A coronal 
split-thickness and apical full-thickness mucoperiosteal flap was used to ensure 
standardization and to allow for the most esthetic outcome (78-80).  Participants were made 
aware of the risk that gingival recession might occur after the periapical microsurgery (81, 
82).   
If necessary, osteotomies were performed using a #6 round carbide bur in a high-speed 
impact air hand piece (Sybron Endo, USA) under copious water irrigation.  The modified 
surgical hand piece used a 45-degree angulated head for visibility and no air ejection to 
prevent emphysema.  Carbide burs were used during the osteotomy to ensure safe and clean 
cutting.  Water irrigation was necessary to minimize thermal injury to the adjacent bone (83, 
84).   
A curettage of the granulation/pathological tissue was completed and the tissue was 
submitted in 10% neutral buffered formation to the UNC Department of Pathology for 
histological evaluation.  Periradicular curettage is necessary for the removal of pathological 
tissue, increased visibility during the surgery, maintenance of hemostasis, and to promote 
healing of the periradicular tissues (85, 86).  
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The apicoectomy was performed with a 0-30% bevel (87) by sectioning 3.0 mm of the 
root tip (88) with a high-speed surgical hand piece using a multi-purpose bur (Dentsply 
Maillefer, Milford, DE) under copious water irrigation.  A resection of at least 3.0 mm of the 
root tip was completed to ensure the best healing potential due to the potential for accessory 
anatomy in the apical portion of the root (88).  A minimal bevel was desired because it 
required a smaller osteotomy, minimal loss to a buccal cortical plate, and eliminates missed 
anatomy (87, 89). 
The resected surface of the root was stained with methylene blue dye (Vista BLUE, 
VISTA Dental Products, USA) and inspected under a microscope using a micro-mirror to 
detect any cracks, fractures, dentinal defects or missed anatomy.  The microscope’s trans-
illumination and the methylene blue aided in detecting the etiology of the non-healing 
endodontic lesions (90).  
The root-end preparation was performed at least 3.0 mm into the canal space 
following the long axis of the tooth using ultrasonic surgical tips (Obtura, Spartan) under 
sterile saline irrigation.  Using ultrasonic surgical tips for the end-root preparation ensured a 
smooth surface (91) and appropriate depth/diameter for placement of the retro-filling material.  
Cleaning deep isthmuses (92) with any other means does not guarantee a favorable result (93, 
94).   
Mineral trioxide aggregate (MTA) was used as a root-end filling material and placed 
into the root-end preparation using the micro-apical-placement system (MAP by Roydent 
Dental Products, Switzerland).  The MTA was mixed according to the manufacturer’s 
directions at a 3:1 powder to liquid ratio using a sterile water solution.  Such a mix provided 
the best handling and biological properties (95).  The placement of the retro-filling material 
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created a seal to prevent the ingress of microorganisms or their byproducts into the canal.  
There are many acceptable retro-filling materials on the market (96, 97).  Evidence suggests 
that MTA provides the best seal (98).  In addition, MTA is biocompatible and has a high pH 
balance upon setting (99-101).  This study used a white MTA-Angulus (Angelus Dental 
Solutions, Londrina, Parana, Brazil) due to its excellent handling property and predictable 
setting time (98, 100, 101).  A post-operative radiograph was taken to confirm the adaptation 
of the root-end filling to root-end preparation.  Following completion of apicoectomy, the 
mucoperiosteal flap was irrigated with copious sterile saline solution. 
The soft-tissues were then repositioned with 5.0 and 4.0 chromic gut sutures to obtain 
primary closure.  The sutures maintain the position of the flap during the initial healing via 
primary intention.  The approximation of the papilla with a smaller suture size gave the best 
esthetic outcome (80, 102).  A local administered submucosally injection of dexamethasone 
4.0 mg or placebo saline solution was then placed at the conclusion of the surgery.   
All participants, regardless of the group in which they were assigned, received the 
same standard post-operative care instructions in verbal and written form.   All participants 
were also given a standardized post-operative surgery prescription for pain control for the 
following three days to be taken if needed.  The prescription included twelve 500 mg tablets 
of Tylenol and twelve tablets of Vicodin 3/500.  Participants were instructed to take both 
tablets every 6 hours if they experienced pain.  Participants were informed not to take more 
than 4 dosages of either medication in a 24 hour period.  
Calibration 
In order to ensure standardization, experienced endodontic residents (second and third 
year residents in the UNC School of Dentistry Graduate Endodontics program) performed all 
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of the periapical microsurgeries.  Prior to participation in this study, each resident had 
performed at least forty endodontic surgeries.  Besides having been trained in the same 
endodontic program, all participating endodontic residents attended a 6-hour lecture and 
watched a video on the standardized surgical protocol prior to the study.  In addition to this 
calibration and standardization, the principal investigator performed or assisted in all of the 
research surgeries.  In order to avoid variances/errors during each procedure, the principal 
investigator, when not performing research surgery, was assisting in order to verify accurate 
papilla-base flap design and flap reflection, standard osteotomy, curettage, root-end resection, 
root end-preparation and the placement of MTA (confirmed with a radiograph), and suturing.  
At the conclusion of every surgery, the primary investigator administered the study protocol 
injections at the mucobuccal fold, adjacent to the target tooth with advancement of the needle 
to approximate the osteotomy site.  As a last safety measure, an attending endodontic faculty 
closely monitored all surgical procedures to ensure quality of care.  
All of the residents and the patients that were participating in the study were informed 
that the principal investigator could intervene at any time during the surgery in order to be 
consistent with the study protocol.  Only the principal investigator performed the follow-up 
evaluations for uniformity of the results.  Given the above, the standardization and oversight 
within an endodontic resident program minimized the chance of error or variance in the 
procedure. 
Required Information and Measurement 
As with all experiments, uniformity and consistency in gathering of information and 
measurements was vital in this study.  Careful consideration and implementation of methods 
and procedures was applied to achieve this goal. 
18
Pain, swelling, bruising and intra-oral healing were the four general areas of recovery 
that the study assessed (Figure 3).  It was necessary that the study measure these areas from the 
standpoint of the patient experience as well as the perspective of the investigator for consistency 
and confirmation.  Photographic and survey documentation at pre and post-operative 
examinations provided data for analytical comparison. 
The patients were instructed to complete the self-evaluation surveys on a 6-point likert-
like visual analog scale for each of the post-operative categories of pain, swelling, bruising, and 
intra-oral healing (Figure 3).  The visual analogue scale is a 
Survey 
psychometric response scale used 
in subjective questionnaires.  Instructions on completion of the survey were given to patients 
post-operatively.  Patients were informed of the characteristic pain, swelling, bruising, and 
intra-oral healing that one would anticipate after such a procedure.  When responding to an 
item in this survey, patients were to indicate their rating by indicating a position along a 
continuous line between two end-points.  Patients made observations at four consecutive 24-
hour intervals and recorded their experience on the survey.  One week after the surgery, patients 
met with the investigator to submit the subject’s survey responses and complete a clinical 
evaluation.  This method allow for the study of absolute levels of healing as well as the rates of 
recovery. 
The pain scale’s purpose was to measure the 
Pain 
patient's pain intensity and duration.  
Often, and as in this study, the pain scale was based on self-reported, observational, and 
physiological data. Self-report was considered primary and was obtained through the daily 
survey sheet.  In addition, the investigator in this study completed patient interviews regarding 
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the different dimensions of pain they experienced to develop consistency among patients in 
the investigator’s rating.  The questions included the site of the pain, such as: “Where 
specifically is the pain?”  The patient was questioned about the type of pain, such as: “What 
does the pain feel like?”, or, “Did the pain impact your everyday life?”  Patients were also 
asked questions regarding exacerbating or relieving factors, such as: “Was there anything that 
made the pain worse or better?”, or, “Was it necessary to take pain relief medication?”  
Patients were instructed to take 500 mg of Tylenol and Vicodin 5/300 in order not to affect 
the observations inflammation.  The relative pain level assessment at each interval was 
regarded as an important element in judging recovery.  Because pain is a subjective and an 
internal experience, the evaluation of pain in this study was best performed by using patient 
self-reports.  This appears to be the most frequently used technique in other pain studies (12, 
15, 25, 29, 30, 38). 
Measuring the change in acute phase reactants is one method of detecting 
inflammation.  The body reacts to inflammation by changing the manufacturing of protein in 
the liver and other protein creating organs.  Acute phase reactants are proteins whose blood 
levels are altered by inflammation.  Two techniques for measuring the change in acute phase 
reactants are the Erythrocyte Sedimentation Rate (ESR) and the C - reactive protein (CRP) 
(112, 113).  These techniques measure the rate at which red blood cells settle over a small 
interval of time.  The rate is directly proportionate to the amount of reactant proteins that are 
Swelling  
Swelling of tissue creates a tight barrier which keeps bacteria out. The increased blood 
supply provides a defense mechanism.  Inflammation’s basic role of isolating injury, 
eliminating invaders and healing damaged tissue is vital. 
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present.  The presence of inflammation increases the amount of proteins in the blood, 
accordingly, the rate of production increases. Unfortunately, the rates are not specific and can 
be altered by other circumstances such as anemia.  The levels for both ESR and CRP can be 
influenced by both gender and age. Finally, and most importantly, inflammation due to other 
causes is not distinguishable from swelling caused by the surgical procedure.  The size of the 
surgical wound and swelling would be relatively small and short in duration in contrast to 
other whole body causes. 
Like pain, inflammation is almost always present with a surgical procedure.  The 
swelling scale’s purpose was to measure the degree and persistence of inflammation in and 
around the site.  In this study, the swelling score was based on self-report by the patient’s 
daily survey observations as well as the investigator’s perspective.  This was deemed to be a 
better approach in contrast to ESR testing given the specific and local nature of the wound, 
duration of recovery and expense and time of ESR testing. 
Innovative measures of bruising, such as Electrical Impedance Measurement, were not 
a practical application in this study (114).  Many methods for measuring bruising are 
destructive in nature as they require penetration, piercing and cutting the tissue.  Infrared 
Bruising 
Periapical surgery results in some degree of injury to the blood vessels in the gingiva.  
A bruise is a traumatic injury of the soft tissues that results in breakage of the local capillaries 
and leakage of red blood cells (22).  This results in a black and blue discoloration appearance 
that, as it fades, becomes green and brown.  This is due to metabolization of the blood cells 
and bilirubin pigment in the skin (114).  Bruising is regarded as an important factor in judging 
recovery as well as gauging the initial tissue damage by the periapical surgery procedure. 
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spectroscopy, hyperspectral imaging, thermal imaging and nuclear magnetic resonance 
imaging are cutting edge technologies that are non-destructive (115-118).  However, after 
consideration, they are unproven technologies in dentistry, impractical for the oral cavity, 
exceeded study time constraints and/or cost prohibitive for this study. 
Unlike pain and inflammation, significant bruising does not always accompany an oral 
surgical procedure.  The bruising scale’s purpose was to measure the degree and persistence 
of bruising in and around the site.  In this study, the bruising score was based on self-report by 
the patient’s daily survey observations as well as the investigator’s perspective.   
The goal of the survey was to provide the patient with a document to record and collect 
data on their recovery experience.  Pain, swelling, bruising (discoloration) and intra-oral healing 
(wound healing) are the four areas of recovery that the patient assessed (Figure 3).  Factual 
information was included on the form such as date, coded patient identifier, investigator’s name, 
Intra-Oral Healing 
Periapical surgery is an invasive procedure.  There is no alternative to the process of 
gingival incisions and root resection.  This process of removing unhealthy tissues and requires 
damaging the surrounding healthy tissue to access the root.  The surgical wound can be a 
source of general discomfort during the recovery period (34).   
Part of surgical wound assessment is wound measurement.  Due to the variation in 
access points and severity of incisions, it was difficult to use a consistent technique among 
cases.  Some patients were unable to retract their cheek and/or lips to evaluate the surgical 
site.  In these instances, patients were asked not to evaluate their intraoral healing to avoid 
disruption of the sutured site. 
Development of the Survey 
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tooth type and the diagnosis. 
The survey was created to be simple and easy to use.  Although English literacy was 
required of patients for participation, minimal instructions with simple words were used in the 
document’s instructions.  Qualitative description of categories can impact how patients use the 
rating scale.  For example, if only the points 1-6 are given without description, some might 
rarely select 6, whereas others may select the category often.  If, instead, "6" is described as 
"near the maximum," the category is more likely to mean the same thing to different people. 
This could apply to all categories and not just the extreme points.  Smiling and frowning 
emoticons were used instead of descriptive words to qualitatively characterize the scale and 
minimize the different interpretations.  Although instructions were to be given to patients post-
operatively when delivering the survey to the patient, it was created to be self-explanatory. 
The likert scale type of question is arguably the most widely used response scale 
featured in surveys.  It is often used to measure attitudes and other factors.  The original scale 
featured five points.  Over time, there have been many discussions and disagreements focused 
on what works best with the likert scale to give the most accurate responses.  Most agree that 
more than seven points on a scale are too much. Studies show that people are not able to 
distinguish a scale greater than seven.   Studies are not conclusive on which number scale is 
best.   
The patients were instructed to complete the self-evaluation surveys on a likert-like 
visual analog scale for each of the post-operative categories of pain, swelling, bruising, and 
intra-oral healing.  When responding to an item in this survey, patients were to indicate their 
rating by indicating a position along a continuous line between two end-points on a scale from 
1 to 6 with “1” representing no symptoms and “6” representing the worst symptoms.  Patients 
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made observations at four consecutive 24-hour intervals and recorded their experience on the 
survey.  One week after the surgery, patients met with the investigator to submit their survey 
responses and complete a clinical evaluation.   
At the one-week meeting, the principal investigators rated the patient’s different healing 
categories.  This allowed for verification of the magnitude of the patient’s ratings.  Ratings at 
the various time intervals allowed for the study of absolute levels of healing as well as the rates 
of recovery in the category over time. 
Double-Blind Procedure 
A blind experiment is an experiment technique in which information about the product 
or service that might lead to bias in the results is concealed from the parties involved until 
after the test.  An open trial where such information is not concealed is vulnerable to such 
intentional or unconscious biases.  The blind technique is used to eliminate human bias or 
influence of the study results. 
A basic blind study would be an experiment where only the subject was unaware of 
information of the product or service being received.  The person or investigator conducting 
the study would know beforehand which subjects were receiving which product or service.  
Researchers suggest that the person or investigator administering the experiment could 
influence the results of such studies by picking and choosing which subjects received which 
product or service.  This would degrade the randomness of the study and could introduce bias. 
If both tester and subject are blinded, the trial is a double-blind trial.  A double-blind 
study requires that neither the subjects of the experiment nor the persons administering the 
experiment know the treatment assignments.  This double-blind procedure is used to guard 
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against both experimenter bias and placebo effects.  This study was performed under double-
blind conditions.  
The IDS at UNC provided control to ensure the double-blind conditions. 
Randomization of who received the drug or placebo injection was performed by the IDS.  IDS 
also maintained custody of the syringes and were the only ones privy to who received which 
injections. Once notified of upcoming surgeries, IDS provided the identically prepared 
syringes the morning of the surgery.  The identity of which patients received which injection 
was unknown to all operators, examiners, and resident surgeons and patients.  Only after the 
completion of the treatments and examinations were the identities of the injections revealed.  
Collection of Data 
The collection of data in this study began with the initial consultation and concluded 
with the post-surgery evaluation. 
Patients were scheduled to return one week after their surgical procedure with their 
completed survey.  Photographs, clinical assessment and notations were made at the post-
operative appointments by the principal investigator.  There were two instances where the 
patients forgot to bring the survey document to their follow-up appointment.  One patient sent 
the survey form to the investigator electronically and the other dictated survey form ratings 
verbally via telephone shortly after their appointment.  Completed survey documents were 
stored in individual envelopes until the data analysis was initiated. 
Upon completion of the surgical procedures, IDS was notified of the closing of the 
study.  The information held by the IDS was then released to the principal investigator.  At this 
point in time, the survey documents were unsealed and the tabulation of results began. 
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The distribution of race that were treated in the dexamethasone group included one of 
Asian descent, seven of African-American descent, three of Hispanic descent and nineteen of 
Caucasian descent.  The distribution of race that were treated in the placebo group included one 
Analysis 
Overview of General Statistics 
All sixty patients completed their surgical procedures, completed their surveys and 
attended their post-operative evaluations.  Upon conclusion of the study, the information held 
by the Investigational Drug Services was then released to the study’s investigator.  General 
statistics were compiled about the total sample and groups before the statistical methodology 
was applied and hypothesis testing began. 
The total sample of the patients consisted of twenty-seven males and thirty-three 
females.  The patients’ ages were categorized as forty years old or under or forty-one and older.  
Fourteen were in the younger age group and forty-six were in the older age group.  The race of 
the total sample included two of Asian descent, thirteen of African-American descent, six of 
Hispanic descent and thirty-nine of Caucasian descent (Table 4).  The distribution of teeth that 
were treated included eight mandibular/anterior, thirteen mandibular/posterior, twenty-five 
maxillary/anterior and fourteen maxillary/posterior. 
The demographics for the dexamethasone group included eleven males and nineteen 
females.  The placebo group demographics of the selected patients were sixteen males and 
fourteen females (Table 1).  The dexamethasone group distribution of age of the total sample 
were five were forty years old or under and twenty-five were age forty-one and older.  The 
placebo group distribution of age of the total sample were nine were forty years old or under 
and twenty-one were age forty-one and older (Table 1). 
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of Asian descent, six of African-American descent, three of Hispanic descent and twenty of 
Caucasian descent.  Seven of the total sample patients were regular smokers of tobacco.  Five of 
the thirty in the Dexamethasone Group were regular smokers of tobacco.  Two of the thirty in 
the placebo group was regular smokers of tobacco. 
The distribution of teeth that were treated in dexamethasone group included four 
mandibular/anterior, six mandibular/posterior, thirteen maxillary/anterior and seven 
maxillary/posterior.  The distribution of teeth that were treated in placebo group included four 
mandibular/anterior, seven mandibular/posterior, twelve maxillary/anterior and seven 
maxillary/posterior. 
Supportive Chi-square and Fisher’s exact tests were performed to determine if the 
distribution of patients between the two groups was significantly different.  The distribution of 
patients based on age, race, gender, tobacco users and teeth did not appear to be significantly 
different between the two groups.  All p-values for the tests were p>0.05 which resulted in 
failure to reject the null hypothesis of equal proportions of patient personal characteristics and 
traits across treatment groups.  This implies that IDS’s randomization of patients provided a 
balanced and normal distribution of patients and their personal traits between the treatment 
groups.  
Statistical Methodology 
Parametric tests apply when data are continuous and normally distributed.  The survey 
scale appears to be discrete (i.e.,1, 2, 3, 4, 5, 6) which means that it is not continuous.  This 
would suggest that a non-parametric test would be the most appropriate.  However, the survey 
scale is on a line with the numbered nodes.  No instructions were given that the patient must 
rate according to a discrete scale.  Patient number four made several fractional ratings during 
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the course of the survey.  This casts doubt on the assumption that the patients view the scale as 
discrete, in which case a parametric test and assumption of continuous data may be more 
appropriate. 
The statistical methodology employed to analyze the survey results and test the null 
hypothesis was the Pearson Chi-Squared test (χ2).  It is a goodness-of-fit statistical model that is 
often used and well known in the scientific research community.  In order to avoid any 
perceived subtleties and fractions in the rating system, the rating from the surveys were grouped 
into two categories.  The “Low” rating category was comprised of ratings 3 and below.  The 
“High” rating category is comprised of ratings above 3. 
The Pearson Chi-square test estimates or approximates how likely it is that an observed 
sampling distribution is due to chance. A Pearson Chi-square test is designed to analyze 
categorical data.  In this study, analysis is of the High versus Low ratings of the patients that 
received dexamethasone versus the placebo.  This test compares the observed data matrix to a 
matrix that distributes the data according to the expectation that the variables are independent.  
When observed data does not match expected data, the likelihood that the variables are 
dependent increases.  With greater differences, the statistical significance increases.  This 
increased significance can disprove the null hypothesis. 
The Pearson Chi-square tests the null hypothesis (H0) that the variables (ratings) are 
independent of the injection that the patient received.  The Null Hypothesis in this Study is: 
There is no statistically significant difference in postoperative complications with a 
single injection of dexamethasone versus a placebo at the time of periapical microsurgery. 
H0: μ1 = μ2 
Where 
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H0 = the null hypothesis, 
μ1 = the distribution of observed data, and 
μ2 = the distribution of expected data 
 
If the null hypothesis is rejected, the alternative hypothesis must be accepted.  The 
Alternative Hypothesis for this study is: 
There is a reduction of postoperative complications with a single injection of 
dexamethasone at the time of periapical microsurgery compared to placebo injection. 
 
Fisher's Exact Test is a statistical significance test that is often used and well known in 
scientific research community in the analysis of contingency tables.  It examines the 
significance of the association (contingency) between two kinds of classification.  It is most 
often used for categorical data that result from classifying objects in two different ways when 
the sample sizes are small.  It derives its name as the P-value significance of the deviation from 
a null hypothesis calculated exactly rather than relying on an approximation by calculating table 
probabilities based on the hyper-geometric probability distribution.   
Results 
The survey ratings for the recovery categories of pain, swelling, bruising, intra-oral 
healing were analyzed individually.  The following reviews the results of the individual 
categorical analysis. 
A general statistical review of ranges and averages was performed first to assess the 
periodic ratings.  This assisted in determining the likely statistic candidates for further statistical 
analysis.  Pearson Chi-Squared test was applied to likely statistics to further assess correlations.  
In cases where statistical significance was found, a Fischer Exact Test was applied as a cross-
check.  As stated before, the ratings from the survey were grouped into high and low rating 
categories for each of the recovery categories at this stage.   
Patients rated the pain that they experienced on the 6-point likert-like scale at 1 day, 2 
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days, 3 days, 4 days and 1 week after the procedure.  The higher the pain level experienced, the 
higher the rating (Tables 2, 3). 
Thirty-two of the sixty patients were symptomatic and were experiencing pain the day 
of the surgical procedure (Table 1).  Those that received an injection of dexamethasone rated 
pain from 1 to 6 with an average rating of 2.5 and a standard deviation of 1.6 after twenty-four 
hours (Table 4).  Those that received a placebo injection rated pain from 1 to 6 with an average 
rating of 3.2 and a standard deviation of 1.7.  At forty-eight hours (two days), those that 
received an injection of dexamethasone rated pain from 1 to 5 with an average rating of 2.0 and 
a standard deviation of 1.3.  Those that received a placebo injection rated pain from 1 to 6 with 
an average rating of 2.4 and a standard deviation of 1.4.  At seventy-two hours, those that 
received an injection of dexamethasone rated pain from 1 to 5 with an average rating of 1.9 and 
a standard deviation of 1.3.  Those that received a placebo injection rated pain from 1 to 6 with 
an average rating of 2.0 and a standard deviation of 1.2.  At ninety-six hours, those that received 
an injection of Dexamethasone rated pain from 1 to 6 with an average rating of 1.6 and a 
standard deviation of 1.2.  Those that received a placebo injection rated pain from 1 to 5 with an 
average rating of 1.6 and a standard deviation of 1.1.  At the clinical evaluation appointment 
one week post-operatively, those that received an injection of dexamethasone rated pain from 1 
to 5 with an average rating of 1.3 and a standard deviation of .9.  Those that received a placebo 
injection rated pain from 1 to 3 with an average rating of 1.3 and a standard deviation of .7. 
Patients rated the swelling that they experienced on the 6-point likert-like scale at 1 day, 
2 days, 3 days, 4 days and 1 week after the procedure.  The more swelling observed by the 
patient, the higher the rating (Table 2, 5). 
Those that received an injection of dexamethasone rated swelling from 1 to 4 with an 
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average rating of 2.4 and a standard deviation of 1.0 after twenty-four hours (Table 6).  Those 
that received a placebo injection rated swelling from 1 to 6 with an average rating of 3.1 and a 
standard deviation of 1.5.  At forty-eight hours, those that received an injection of 
dexamethasone rated swelling from 1 to 5 with an average rating of 2.6 and a standard deviation 
of 1.1.  Those that received a placebo injection rated swelling from 1 to 6 with an average rating 
of 3.1 and a standard deviation of 1.4.  At seventy-two hours, those that received an injection of 
dexamethasone rated swelling from 1 to 5 with an average rating of 2.3 and a standard deviation 
of 1.2.  Those that received a placebo injection rated swelling from 1 to 6 with an average rating 
of 2.5 and a standard deviation of 1.3.  At ninety-six hours, those that received an injection of 
dexamethasone rated swelling from 1 to 4 with an average rating of 1.8 and a standard deviation 
of 1.0.  Those that received a placebo injection rated swelling from 1 to 5 with an average rating 
of 1.9 and a standard deviation of 1.2.  At the clinical evaluation appointment one week post-
operatively, those that received an injection of dexamethasone rated swelling from 1 to 5 with 
an average rating of 1.3 and a standard deviation of 0.8.  Those that received a placebo injection 
rated swelling from 1 to 3 with an average rating of 1.3 and a standard deviation of 0.5. 
Observing the general statistic of range, average, rates of change and standard deviation 
of the ratings, the dexamethasone group appears to have performed similar the placebo group 
from day 2 and after.  However, the day 1 average rating of 3.1 for the placebo group was 
significantly higher than the 2.4 for the dexamethasone group (Figure 5).  This warrants further 
statistical analysis which has been done below.   
The Pearson’s Chi-square test was performed on the 2 x 2 matrix of high and low rating 
scores for the day 1 of swelling. 
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Actual Frequency Distribution 
 High 
Rating   
Low 
Rating 
 
Total 
dexamethasone 4 26 30 
placebo 12 18 30 
Total Observations 16 44 60 
 
Expected Frequency Distribution 
 High 
Rating   
Low 
Rating 
 
Total 
Dexamethasone 8 22 30 
placebo 8 22 30 
Total Observations 16 44 60 
 
 
The test was done at the level of significance of 5% (α): Level of significance =  α  = 
.05, or 5%.  Given that the distribution table is a 2 x 2 matrix, the degrees of freedom is equal to 
one: Degrees of Freedom = df = 1. 
The pertinent Chi-square values are as below: 
 
α = .5    .1 .05 .02 .01 
1 df . 455 2.706 3.841 5.412 6.635 
2df 1.386 4.605 5.991 7.824 9.210 
3df 2.366 6.251 7.815 9.837 11.345 
 
The Chi-square value of 3.841 is the benchmark that must be exceeded for the null 
hypothesis to be rejected (Figure 4).  The Chi-square value calculated for the swelling ratings 
distribution was 5.455
 
.   
As a confirmation, the Fischer Exact Test was performed.  A one-tail test was performed 
in the following Fischer Exact Test formulation:  
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 Where, 
a = high ratings for dexamethasone group observed 
b = low ratings for dexamethasone group observed 
c = high ratings for placebo group observed 
d = low ratings for placebo group observed 
n = total population of ratings 
The resulting P-value from the Fischer Exact Test for day-one swelling ratings was 
equal to 0.0195.   
Patients rated the bruising that they experienced on the 6-point likert-like scale at 1 day 
(24 hours), 2 days (48 hours), 3 days (72 hours), 4 days (96 hours) and 1 week after the 
procedure (Tables 2, 7).  The more bruising and discoloration observed, the higher the rating. 
Those that received an injection of dexamethasone rated bruising from 1 to 5 with an 
average rating of 1.7 and a standard deviation of 1.4 after twenty-four hours (one day) (Table 
8).  Those that received a placebo injection rated bruising from 1 to 6 with an average rating of 
2.0 and a standard deviation of 1.4.  At forty-eight hours (two days), those that received an 
injection of dexamethasone rated bruising from 1 to 6 with an average rating of 2.0 and a 
standard deviation of 1.5.  Those that received a placebo injection rated bruising from 1 to 6 
with an average rating of 2.0 and a standard deviation of 1.4.  At seventy-two hours (three 
days), those that received an injection of dexamethasone rated bruising from 1 to 6 with an 
average rating of 2.0 and a standard deviation of 1.5.  Those that received a placebo injection 
rated bruising from 1 to 6 with an average rating of 1.8 and a standard deviation of 1.2.  At 
ninety-six hours (four days), those that received an injection of dexamethasone rated bruising 
from 1 to 6 with an average rating of 1.9 and a standard deviation of 1.4.  Those that received a 
placebo injection rated bruising from 1 to 6 with an average rating of 1.8 and a standard 
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deviation of 1.3.  At the clinical evaluation appointment one week post-operatively, those that 
received an injection of dexamethasone rated bruising from 1 to 6 with an average rating of 1.6 
and a standard deviation of 1.1.  Those that received a placebo injection rated bruising from 1 to 
6 with an average rating of 1.4 and a standard deviation of 1.1. 
Patients rated the intra-oral healing that they experienced on the 6-point likert-like scale 
at 1 day, 2 days, 3 days, 4 days and 1 week after the procedure (Tables 2, 9).  The more trauma 
and damage tissue observed, the higher the rating.  Ten of the patients were unable to provide 
ratings for intra-oral healing due to the sutures that were placed after the surgical procedure.  
There was concern that by opening their mouth to visually inspect the healing process, tearing 
of the sutured tissue would occur.  Five patients from the dexamethasone group and five 
patients from the placebo group did not render ratings at one time interval or another during the 
ratings time period.  
Those that received an injection of dexamethasone rated intra-oral healing from 1 to 5 
with an average rating of 2.6 and a standard deviation of 1.3 after twenty-four hours (Table 10).  
Those that received a placebo injection rated intra-oral healing from 1 to 6 with an average 
rating of 3.3 and a standard deviation of 1.6.  At forty-eight hours, those that received an 
injection of dexamethasone rated intra-oral healing from 1 to 5 with an average rating of 2.7 and 
a standard deviation of 1.3.  Those that received a placebo injection rated intra-oral healing from 
1 to 6 with an average rating of 2.8 and a standard deviation of 1.7.  At seventy-two hours, those 
that received an injection of dexamethasone rated intra-oral healing from 1 to 5 with an average 
rating of 2.2 and a standard deviation of 1.2.  Those that received a placebo injection rated intra-
oral healing from 1 to 6 with an average rating of 2.5 and a standard deviation of 1.3.  At 
ninety-six hours, those that received an injection of dexamethasone rated intra-oral healing from 
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1 to 5 with an average rating of 1.9 and a standard deviation of 1.1.  Those that received a 
placebo injection rated intra-oral healing from 1 to 5 with an average rating of 2.0 and a 
standard deviation of 1.0.  At the clinical evaluation appointment one week post-operatively, 
those that received an injection of dexamethasone rated intra-oral healing from 1 to 5 with an 
average rating of 1.6 and a standard deviation of 1.0.  Those that received a placebo injection 
rated intra-oral healing from 1 to 4 with an average rating of 1.6 and a standard deviation of 0.7. 
Observing the general statistic of range, average, rates of change and standard deviation 
of the ratings, the dexamethasone Group appears to have performed similar the placebo group 
from day 2 and after.  However, the day 1 average rating of 3.3 for the placebo group was 
significantly higher than the 2.6 for the dexamethasone group.  This warrants further statistical 
analysis which is performed below.   
As with the analysis of swelling and inflammation, the Pearson’s Chi-square test was 
performed on the 2 x 2 matrix of high and low rating scores for the day 1 of intra-oral healing. 
Actual Frequency Distribution 
 High 
Rating   
Low 
Rating 
 
Total 
dexamethasone 6 19 25 
placebo 12 13 25 
Total Observations 18 32 50 
 
Expected Frequency Distribution 
 High 
Rating   
Low 
Rating 
 
Total 
dexamethasone 9 16 25 
placebo 9 16 25 
Total Observations 18 32 50 
 
The test was done at the level of significance of 5% (α): Level of significance =  α  = 
.05, or 5%.  Given that the distribution table is a 2 x 2 matrix, the degrees of freedom is equal to 
one: Degrees of Freedom = df = 1. 
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The pertinent Chi-square values are as below: 
 
α = .5    .1 .05 .02 .01 
1 df . 455 2.706 3.841 5.412 6.635 
2df 1.386 4.605 5.991 7.824 9.210 
3df 2.366 6.251 7.815 9.837 11.345 
 
The Chi-square value of 3.841 is the benchmark that must be exceeded for the null 
hypothesis to be rejected.  The Chi-square value calculated for the intra-oral healing ratings 
distribution was 3.125
 
Where, 
a = high ratings for dexamethasone group observed 
b = low ratings for dexamethasone group observed 
c = high ratings for placebo group observed 
d = low ratings for placebo group observed 
n = total population of ratings 
 
The resulting P-value from the Fischer Exact Test for day-one intra-oral healing ratings 
was equal to 0.0977.   
Discussion 
.   
As a confirmation and since the Pearson Chi-square test was near the 10% level of 
significance, the Fischer Exact Test was performed.  Like the test performed for swelling and 
inflammation, a one-tail test was performed in the following Fischer Exact Test formulation:  
Patients were informed that they could take 500 mg of Tylenol and Vicodin 5/300 for 
pain relief if necessary.  Most patients experience pain post-operatively in the first twenty-four 
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hours.  This was expected since a glucocorticoid steroid is known for its recovery properties and 
not for its anesthetizing effects.  Forty-three of the sixty patients used Tylenol and/or Vicodin 
during the first twenty-four  hours post-operatively.  This may render the resulting affects of 
dexamethasone on pain inconclusive. 
This is further supported by observing the rates of change in ratings from one time 
interval to the next between dexamethasone versus the placebo.  The placebo group experienced 
a greater average pain rating change from day 1 to day 2 than the dexamethasone group.  The 
average pain rating for the placebo group decreased 0.83.  The average pain rating for the 
dexamethasone group only decreased 0.52.  The trend continued from day 2 to day 3.  The 
average pain rating for the placebo group decreased 0.43.  The average pain rating for the 
dexamethasone group only decreased 0.12.   
Improvement stabilized at this point and the rate of change was similar for the change in 
ratings between day 3 and day 4.  The average pain rating for the placebo group dropped 0.33.  
The average pain rating for the dexamethasone group decreased 0.30.  And finally, the average 
pain rating for the placebo group decreased 0.30 from the 4th day to the 1 week appointment.  
For the same corresponding period, the average pain rating for the dexamethasone group 
decreased a comparable 0.27. 
A supportive observation of the rating system is the average absolute ratings and 
average rates of change provided for day 3 and 4 and at the 1 week time intervals were nearly 
the same for both groups.  The effects of 4.0 mg injection of dexamethasone were expected to 
cease after approximately 36 to 48 hours.  During this post-operative period, patients would 
experience an untreated recovery path and pain level.  The strikingly similar rating scores and 
changes support the study’s assumption that patients’ subjective judgments in rating pain are 
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comparable.  The standard deviation statistic at the various time intervals for each of the groups 
during this post-operative period is approximately one rating point.  The expected variation in 
pain actually experienced by patient would likely account for most of the variance rather than 
significantly different subjective rating scales. 
The swelling statistics on day 2 and after are consistent through the time intervals and 
quite similar.  The subtle difference appears statistically insignificant.  A supportive observation 
of the rating system is the average absolute ratings at the one week follow-up appointment.  
This was nearly the same for both groups and the principal investigator.  At this point of the 
post-operative period, patients’ swelling would have neared completion.  The strikingly similar 
rating scores support the study’s assumption that patients’ subjective judgments in rating 
swelling are comparable.  
In review of the bruising rating general statistic of range, average, rates of change and 
standard deviation of the ratings, the placebo group appears to have performed slightly better 
than the dexamethasone group.  The statistics are consistent through the time intervals and quite 
similar.  The subtle difference is statistically insignificant. 
A supportive observation of the rating system is the average absolute ratings at the one 
week follow-up appointment.  This was nearly the same for both groups and the investigator.  
At this point of the post-operative period, patients’ bruising would have peaked and begun to 
subside.  The strikingly similar rating scores support the study’s assumption that patients’ 
subjective judgments in rating bruising are comparable.  
The intra-oral healing statistics on day 2 and after are consistent through the time 
intervals and quite similar.  The subtle difference appears statistically insignificant.  A 
supportive observation of the rating system is the average absolute ratings at the one week 
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follow-up appointment was nearly the same for both groups and the investigator.  At this point 
of the post-operative period, patients’ intra-oral healing would have neared completion.  The 
strikingly similar rating scores support the study’s assumption that patients’ subjective 
judgments in rating intra-oral healing are comparable.   
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CHAPTER 2:  FORMATTED FOR THE JOURNAL OF ENDODONTICS 
Key Words: Apicoectomy, Endodontic Microsurgery, Inflammation, Corticosteroids, 
Dexamethasone, Outcome 
Abstract 
Introduction:  Substantial inflammation, bruising and pain have been an inevitable 
consequence of oral surgery.  There is limited data on assessing post-operative complication 
following periapical microsurgery using injectable corticosteroids.  The purpose of this 
prospective, double blind randomized clinical trial is to evaluate the short-term post-operative 
healing of endodontic periapical microsurgery following the local administration of 
dexamethasone.  
Methods: Sixty patients received a single local submucosal injection of either 4.0 mg of 
dexamethasone or a placebo saline solution at the conclusion of a standardized periapical 
microsurgery.  A self-administered survey provided data for analytical comparison.  Data was 
analyzed at a significance level of p=.05 using Chi square and Fisher’s Exact tests. 
Results: Subjects who received the dexamethasone injection reported less swelling 24 hours 
post-periapical microsurgery compared to the placebo with a statistically significant result of 
p < .02.  Improvements in pain, bruising and intra-oral healing were not statistically 
significant. 
Conclusions: This study demonstrated that a single submucosal low-dosage dexamethasone 
injection following periapical microsurgery reduces swelling at 24 hours post-operatively and 
can potentially lessen post-operative sequela. 
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Initial endodontic therapy does not produce an acceptable treatment outcome in 
approximately one-third of all cases and results in the need for endodontic retreatment (
Introduction 
1).  In 
an analysis of surgical and non-surgical retreatment therapies (2), research shows that healing 
rates are not substantially different between the two approaches (3).   
Periapical surgery is regarded as an integral part of modern endodontics (4, 5).  
Endodontic surgeries account for approximately 6 to 10% of the typical endodontic practice 
treatments (6, 7) and are considered an extension of non-surgical treatments.  Based on short 
and long term evaluations, periapical surgeries have a 91 to 97% healing success rate (8, 9) 
making periapical microsurgery a good treatment option.  Research indicates that substantial 
inflammation, pain, and bruising have long been an inevitable consequence of oral surgery 
(10).  The anti-inflammatory efficacy of corticosteroids has led to their extensive use after 
surgical procedures (11-14).  Dexamethasone has been successful in reducing the post-
operative sequelae (8, 11-21), edema, and inflammation that typically accompany oral 
surgery.  Endodontic microsurgery studies have shown some success using oral 
dexamethasone both preoperatively and postoperatively (15, 20, 21).  One endodontic surgical 
model suggested that the routine use of oral dexamethasone is a safe method to reduce pain 
and swelling after endodontic surgery (8).  However, no post-operative symptoms were 
analyzed in that model.  The purpose of this double blind randomized clinical study is to 
evaluate short-term post-operative healing of endodontic microsurgery using a 4.0 mg local 
submucosal injection of the dexamethasone at the conclusion of periapical microsurgery. 
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Materials and Methods 
Sixty adult patients (27 men and 33 women) participated in this study (Table 1).  All 
participants were in good health as verified by the health history questionnaire and 
examination.  Criteria for inclusion were as follows: relatively healthy adult participants 18 
years of age or older without chronic pain conditions or underlying chronic systemic 
conditions.  All teeth with persistent endodontic lesions after retreatment or initial root canal 
therapy where retreatment is not possible (post, anatomy, iatrogenic complications) were 
eligible.  Exclusion criteria:  (1) Miller Class III/IV mobility, (2) compromised crown to root 
ratio, (3) combined endodontic-periodontic lesions, (4) chronic pain, (5) systemic medical 
conditions, (6) pregnancy, (7) allergy to dexamethasone, (8) allergy to local anesthetics or 
sulfites, (9) younger than 18 years of age, (10) acute systemic conditions.  The University of 
North Carolina at Chapel Hill (UNC) Institutional Review Board (IRB) approved the study 
(IRB protocol number 13-2336).  Written and informed consents were obtained from each 
patient prior to a surgical intervention.   
Using a double-blind randomized controlled setting, the 60 patients were randomly 
assigned to the intervention (4.0 mg of dexamethasone) or placebo (saline solution) groups 
with 30 patients in each group.  Randomization was performed by the Investigational Drug 
Services (IDS protocol number 2519) at the UNC hospital.   Patients were required to have 
three appointments.  The first appointment was a screening appointment to review the medical 
history, clinical and radiographic evaluation to determine qualification.  If a patient qualified 
for the study, the next appointment was the periapical microsurgery.  Lastly, the patient 
returned for the one week follow-up appointment post-operatively.  
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With the exception of incisions and suturing, all microsurgical procedures were 
performed using a Surgical Operating Microscope (Global G6 Microscope, Global Surgical 
Corporation, St. Louis, MO) using modern microsurgical techniques.  After profound 
anesthesia with 2% Lidocaine with 1:100,000/1:50,000 of epinephrine, a split-thickness 
papilla-base muco-periosteal flap was used to ensure standardization and to allow for the most 
esthetic outcome.  If necessary, osteotomies were performed using a #6 round carbide bur in a 
high-speed impact air hand piece (Sybron Endo, USA) under copious water irrigation.  A 
curettage of granulation/pathological tissue was performed and tissues were submitted to the 
UNC Department of Pathology for histological analysis.  A resection of apical 3 mm of the 
root performed with 0-30% bevel.  The resected surface of the root was stained with 
methylene blue dye (Vista BLUE, VISTA Dental Products, USA) and inspected under a 
microscope using a micro-mirror to detect any cracks, fractures, dentinal defects or missed 
anatomy.  The root-end preparation was performed at least 3.0 mm into the canal space 
following the long axis of the tooth using ultrasonic surgical tips (Obtura, Spartan) under 
saline irrigation.  Mineral trioxide aggregate (MTA – Angelus Dental Solutions, Londrina, 
Parana, Brazil) was used as a root-end filling material and placed into the root-end preparation 
using the micro-apical-placement system (MAP by Roydent Dental Products, Switzerland).  
The soft-tissues were approximated and primary closure was achieved with 5.0 and 4.0 
chromic gut sutures.  A local submucosal injection of dexamethasone 4.0 mg or placebo 
saline solution was then placed at the conclusion of the surgery.   
Irrespective of the group assigned, patients received the same standard post-operative 
care instructions in verbal and written form.   All participants were given a standard post-
operative surgery prescription for pain control for the following three days to be taken if 
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needed.  The prescription included 12 tablets each of Tylenol 500 mg and Vicodin 3/500.  
Participants were advised to take both tablets every 6 hours if they experienced pain while not 
taking more than 4 dosages in a 24 hour period. 
All patients were provided with a take-home survey to record their pain, swelling, 
external bruising, and intra-oral healing recovery on a Likert-like 6 point visual analog scale 
at 24, 48, 72, 96 hours and at day 7.  The 6 point visual analog had a continuous line that 
ranged from 1 to 6 with “1” being no symptoms and “6” being severe symptoms (Figure 3).  
Patients were instructed to record the amount of pain medication consumed on the survey 
form.  Upon return for the one-week follow-up appointment, the primary investigator used the 
same survey form to rate the same post-operative recovery categories.  
In order to ensure standardization, endodontic residents (second and third year 
graduate endodontic residents at UNC School of Dentistry) performed all of the periapical 
microsurgeries.  Prior to participation in this study, each endodontic resident had previously 
performed at least forty endodontic surgeries.  Besides having been trained in the same 
endodontic program, all participating endodontic residents attended a 6-hour lecture and 
watched a video on the standardized surgical procedures prior to the study.  In addition to this 
calibration and standardization, the principal investigator either performed or assisted in all of 
the research surgeries.  In order to avoid variances or errors during each procedure, the 
principal investigator, when not performing research surgery, was assisting in order to verify 
accurate papilla-base flap design and flap reflection; standardized osteotomies, curettage, 
root-end resection, root end-preparation and the placement of MTA (confirmed with a 
radiograph), and suturing.  The primary investigator performed the injections at the 
conclusion of each surgery.  All of the residents and the patients that were participating in the 
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study were informed that the principal investigator could intervene at any point during the 
surgery in order to be consistent with the protocol.  Only the principal investigator performed 
the follow-up evaluations for uniformity of the results.  
Upon completion of the study, the data was statistically analyzed.  Randomization of 
patient group assignment was performed by IDS.  The proportions of each group’s gender, 
age of subjects, tobacco use, or race, or tooth type were assessed by using the randomization 
test as a cross-check.  Correlation tests between the ratings and the demographic traits were 
tested using the Mantel-Haenszel test (Table 2). 
A 2 x 2 matrix distribution table was created of high and low ratings of each group.  The 
Pearson Chi-square is used to test the difference in recovery ratings.  A two-tailed test with no 
corrections was utilized.  The test was done at the level of significance of p-value = .05 with one 
degree of freedom.  A normal and continuous distribution was confirmed and used in the test.  
In instance where statistical significance was calculated, it was confirmed with the one-tailed 
Fischer Exact Test. 
Results 
 There was no statistically significant difference between the two group’s participants 
based on gender, age of subjects, tobacco use, or race, or tooth type (p>.05) (Table 2).  After 
48 hours, the pain, swelling, bruising and intraoral healing ratings by the two groups were 
practically indistinguishable with even general statistics (Tables 2, 4, 6, 8, 10).  The greatest 
statistical difference occurs at 24 hours post-operatively for each category. 
There was no statistically significant difference between the two group’s pain and 
bruising ratings at any time interval.  At 24 hours post-operatively, the intraoral healing 
achieved it greatest significance narrowly missing the statistically significance benchmark 
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(3.125 < 3.841).  The Fischer Exact Test was performed and supported this result with a 
p=.0977. 
At the same point in time, the swelling improvement not only exceeds the benchmark 
(5.455 > 3.841), but the p-value = .02 mark as well (5.455 > 5.412).  The Fischer Exact Test 
was performed and confirmed the result with a p=.0195 which translates to more than 98% 
confidence. 
Discussion 
This study shows that a dexamethasone injection may reduce some post-operative 
sequelae.  The effect of dexamethasone was most pronounced with a reduction of swelling at 
24-hours post-operatively, the time at which swelling usually peaks.  This study’s data on 
swelling is consistent with the results of other studies in the oral surgery literature (14, 16, 17, 
19, 20).  No statistically significant correlations were found between gender, age of subjects, 
tobacco use, or race, or tooth type versus recovery ratings.  This study’s finding that the 
efficacy of dexamethasone in the maxilla and mandible was similar and is supported by other 
research that found dexamethasone is absorbed from the injection site and distributes between 
both maxilla and mandible similarly (22).  
This study used a very conservative single 4.0 mg dexamethasone dosage to ensure a 
safe, effective and efficient dosage.  Corticosteroids at higher levels with multiple dosages 
have been found to cause adrenal fatigue and can mask symptoms of bacterial infection (23).  
This study’s dosage level of dexamethasone and its expected duration of action does not 
suppress the adrenal glands and, therefore, does not pose any risk of stress intolerance.  
Research has shown that a one-week course of corticosteroids is not only safe, but very 
effective in reducing post-surgical dental pain and swelling (23).  An important finding of that 
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study was that patients required less NSAIDs and narcotics to control their post-operative 
pain.  A single dose of corticosteroids has also been proven to be safe and effective in terms 
of reducing pain and swelling by other research (24).  A study by Czerwinski concluded that a 
single large intravenous dose of dexamethasone (2.0 milligrams per kilogram of body weight) 
does not have any harmful side effects (24).  This instance study used a single small dose of 
4.0 mg of dexamethasone (17) which is much less than what was used in the Czerwinski 
study.  Previous studies found that a single local submucosal injection of 4.0 mg of 
dexamethasone was proven to be as effective as 8.0 mg in reducing post-operative 
complications (17).   
This study utilized a smaller dosage of dexamethasone in order to minimize potential 
side effects.  A single dose of corticosteroid at this low level has no harmful effects (24).  Some 
research suggests giving corticosteroids pre-operatively (11, 12, 14) in consideration of the 
delayed therapeutic effect (25-27).  It is suggested that dexamethasone may inhibit the initial 
step of the inflammatory cascade (28).   It is further suggested that an injectable form of 
corticosteroids may induce a more rapid affect (29) than if dexamethasone is taken orally.  
While the oral administration of dexamethasone is convenient and clinically effective (11, 21), 
patient compliance and the need for repeated doses to sustain adequate steroid concentration 
can become problematic with oral administration.  It is more predictable and effective to inject 
the dexamethasone at the time of the surgery rather than using the oral route. 
There is little formal conformation of dexamethasone’s efficacy in controlled studies.  
Previous research has provided inconsistent results due to the lack of uniformity in study 
design and varying measurement techniques.  Recommended dosage and routes of 
dexamethasone administration have varied as well.  One oral surgery study failed to show any 
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significant improvement in swelling and pain following treatment with a 4.0 mg oral dose of 
dexamethasone (14).  However, other research has shown significant swelling reduction with 
8.0 mg of dexamethasone taken orally (19).  Furthermore, other oral surgery research has 
shown that 4.0 mg of dexamethasone injected submucosally had the same efficacy as 8.0 mg 
in reducing swelling 24-hours post-operatively (17).  That same study failed to demonstrate 
any impact on pain using both doses of dexamethasone.  Another endodontic surgery study 
suggests administering corticosteroids routinely afterwards  to prevent swelling and pain and 
is described as an effective and safe method (8).  However, post-operative symptoms were not 
analyzed by that particular study.  Other traditional periapical surgery research reported 
swelling and pain in all patients undergoing treatment although no steps were taken to prevent 
swelling (10).   
Patients self-assessed their pain, swelling, bruising, and intra-oral healing on a 
commonly accepted visual analog scale used in dental and medical research (30, 31). Each 
patient rated and recorded the degree of the pain, swelling, bruising and intra-oral healing 
(when possible) at day 1, 2, 3, 4 and 7.  The scale ranged from 1 to 6 where “1” referred to no 
symptoms and “6” referred to severe symptoms.  Visual analogs scores are commonly 
combined during the statistical analysis (32, 33).  In this study, some intra-oral healing rates 
were not recorded by patients due to the risk of suture tearing.   This study combined scores of 
less than 3 in the “low” rating category and scores of more than 3 in a “high” rating category.  
There was no statistically significant difference in this study between the 
dexamethasone group and the placebo group for the pain and bruising categories at any point 
in time (Figure 6).  The failure to reduce pain is consistent with other oral surgery research 
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findings (17, 19, 21).  Pre-operative symptoms did not significantly alter pain ratings for 
either group in this study contrary to previous studies (15, 34).   
The only statistically significant improvement was in the swelling recovery category 
of the dexamethasone group compared to the placebo group at 24 hours post-operatively.  The 
recovery category “intraoral healing” category narrowly missed the statistically significant 
benchmark (p<0.05) at 24 hours post-operatively. It appears that the anti-inflammatory effect 
of 4.0 mg submucosal dexamethasone is either minimal after 24 hours or an insufficient 
dosage was administered to observe a more pronounced improvement later than 24 hours.   
Routine antibiotics were not prescribed since no patients exhibited symptoms of 
malaise or fever.  This protocol is supported by a study that found that routine antibiotic 
therapy is not necessary at the time of oral surgery with the use of corticosteroids (21, 35).     
Antibiotics were only prescribed in two instances in this study where exposure of the 
maxillary sinus occurred during the surgical procedure; one patient was in the dexamethasone 
group and the other patient was in the placebo group.  The use of antibiotics did not impact 
the results as patients were split between the groups.   
In conclusion, this study demonstrated that a single low-dose submucosal 
dexamethasone injection minimizes swelling 24 hours following periapical microsurgery and 
can potentially lessen post-operative sequela.  Future comparative studies are needed in this 
field to establish a protocol on reducing post-operative complications. 
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Dexamethasone Placebo
Sex:
Females 19 14
Males 11 16
Age:
40 and Under 5 9
Over Age 40 25 21
Tooth Type:
Anterior / Mandibular 4 4
Anterior / Maxillary 13 12
Posterior / Mandibular 6 7
Posterior / Maxillary 7 7
Race:
Asian 1 1
African American 7 6
Hispanic 3 3
Caucasian 19 20
Tobacco:
User 5 2
Non - User 25 28
Symptomatic Day of Surgery:
Displays Symptoms 18 14
No Symptoms 12 16
Case Distribution
Table  1
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Low Ratings High Ratings Total Low Ratings High Ratings Total P-Value
Day 1:
Pain 21 9 30 16 14 30 0.1843
Swelling 26 4 30 18 12 30 0.0195
Bruising 26 4 30 25 5 30 0.7177
Intra-Oral 19 6 25 13 12 25 0.0771
Day 2:
Pain 25 5 30 23 7 30 0.5186
Swelling 22 8 30 19 11 30 0.4051
Bruising 25 5 30 26 4 30 0.7177
Intra-Oral 17 8 25 17 9 26 0.8430
Day 3:
Pain 25 5 30 26 4 30 0.7177
Swelling 23 7 30 26 4 30 0.3169
Bruising 24 6 30 27 3 30 0.2781
Intra-Oral 22 3 25 20 6 26 0.2996
Day 4:
Pain 27 3 30 26 4 30 0.6876
Swelling 28 2 30 26 4 30 0.3894
Bruising 26 4 30 26 4 30 1.0000
Intra-Oral 23 2 25 24 2 26 0.2996
1 Week:
Pain 28 2 30 30 0 30 0.1503
Swelling 29 1 30 30 0 30 0.3132
Bruising 29 1 30 29 1 30 1.0000
Intra-Oral 24 1 25 25 1 26 0.9674
Table  2
Summary of Pain, Swelling, Bruising, Intra-Oral Healing
by High and Low Ratings
Dexamethasone Placebo
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Patient
Number Treatment 1 Day 2 Days 3 Days 4 Days 1 week Investigator
1 Dexamethasone 1 1 1 1 1 1
2 Placebo 2 1 1 1 1 1
3 Placebo 1 1 1 1 1 1
4 Dexamethasone 2 1.5 1 1 1 1
5 Dexamethasone 1 1 1 1 1 1
6 Placebo 1 1 1 1 1 1
7 Placebo 2 1 1 1 1 1
8 Dexamethasone 4 3 3 3 1 1
9 Dexamethasone 1 1 1 1 1 1
10 Placebo 2 3 2 1 1 1
11 Placebo 3 3 2 1 1 1
12 Dexamethasone 3 1 2 1 1 1
13 Dexamethasone 2 1 1 1 1 1
14 Placebo 2 2 2 2 1 1
15 Dexamethasone 5 4 5 1 1 1
16 Dexamethasone 1 1 1 1 1 1
17 Placebo 5 3 2 1 1 1
18 Placebo 1 1 1 1 1 1
19 Placebo 3 2 1 1 1 1
20 Placebo 5 4 3 2 1 2
21 Placebo 4 2 2 1 1 1
22 Dexamethasone 1 1 1 1 1 1
23 Dexamethasone 1 1 1 1 1 1
24 Dexamethasone 3 2 1 1 1 1
25 Dexamethasone 1 1 1 1 1 1
26 Placebo 5 1 1 2 1 1
27 Dexamethasone 1 1 1 1 1 1
28 Dexamethasone 4 1 1 1 1 1
29 Placebo 5 2 1 1 1 1
30 Placebo 5 4 4 4 2 2
Pain Ratings
Patient Survey Ratings for Pain  -  Raw Data
Table  3
Page 1 of 2
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Patient
Number Treatment 1 Day 2 Days 3 Days 4 Days 1 week Investigator
31 Placebo 3 2 2 1 1 1
32 Placebo 1 1 1 1 1 1
33 Placebo 1 1 1 1 1 1
34 Dexamethasone 4 5 5 4 2 1
35 Dexamethasone 1 1 1 1 1 1
36 Dexamethasone 4 4 4 6 4 2
37 Dexamethasone 1 3 3 2 1 1
38 Placebo 5 4 2 2 1 1
39 Dexamethasone 1 1 1 1 1 1
40 Placebo 6 6 6 5 3 1
41 Placebo 4 3 4 4 3 1
42 Dexamethasone 1 1 1 1 1 1
43 Dexamethasone 3 2 2 1 1 1
44 Placebo 5 3 2 1 1 1
45 Placebo 4 4 4 4 3 1
46 Placebo 1 1 1 1 1 1
47 Dexamethasone 6 5 4 2 1 1
48 Dexamethasone 5 2 1 1 1 1
49 Dexamethasone 5 4 3 2 2 2
50 Placebo 6 5 2 2 2 2
51 Dexamethasone 3 3 2 2 1 1
52 Dexamethasone 1 1 1 1 1 1
53 Placebo 1 1 1 1 1 1
54 Placebo 4 2 1 1 2 1
55 Placebo 5 4 3 2 2 2
56 Dexamethasone 5 3 4 4 5 2
57 Dexamethasone 3 2 1 1 1 1
58 Placebo 2 2 2 1 1 1
59 Dexamethasone 1 1 1 1 1 1
60 Placebo 3 2 2 1 1 1
Patient Survey Ratings for Pain  -  Raw Data
Pain Ratings
Table  3
Page 2 of 2
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Average 
Rating Range
Standard 
Deviation
Dexamethasone :
Day 1  /  24 Hours 2.5 1 to 6 1.6
Day 2  /  48 Hours 2.0 1 to 5 1.3
Day 3  /  72 Hours 1.9 1 to 5 1.3
Day 4  /  96 Hours 1.6 1 to 6 1.2
1 week 1.3 1 to 5 0.9
Investigator's Rating at
1 week appointment 1.1 1 to 2 0.3
Placebo :
Day 1  /  24 Hours 3.2 1 to 6 1.7
Day 2  /  48 Hours 2.4 1 to 6 1.4
Day 3  /  72 Hours 2.0 1 to 6 1.2
Day 4  /  96 Hours 1.6 1 to 5 1.1
1 week 1.3 1 to 3 0.7
Investigator's Rating at
1 week appointment 1.1 1 to 2 0.3
General  Statistics  of  the Dexamethasone
and  Placebo  Group's  Pain  Ratings
Table  4
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Patient
Number Treatment 1 Day 2 Days 3 Days 4 Days 1 week Investigator
1 Dexamethasone 1 1 1 1 1 1
2 Placebo 2 1 1 1 1 1
3 Placebo 1 1 1 1 1 1
4 Dexamethasone 3 3 3 2 1 1
5 Dexamethasone 2 2 1 1 1 1
6 Placebo 1 1 1 1 1 1
7 Placebo 2 2 2 1 1 1
8 Dexamethasone 4 4 3 3 1 1
9 Dexamethasone 2 4 3 2 1 1
10 Placebo 1 3 2 3 1 1
11 Placebo 3 4 3 1 1 1
12 Dexamethasone 2 1 2 1 1 1
13 Dexamethasone 3 2 1 1 1 1
14 Placebo 1 2 2 2 2 1
15 Dexamethasone 3 4 5 1 1 1
16 Dexamethasone 2 2 1 1 1 1
17 Placebo 4 5 3 1 1 1
18 Placebo 3 3 3 3 2 1
19 Placebo 5 4 3 2 1 3
20 Placebo 4 3 2 1 1 1
21 Placebo 4 5 3 2 1 1
22 Dexamethasone 1 2 1 1 1 1
23 Dexamethasone 1 2 3 2 1 1
24 Dexamethasone 2 3 1 1 1 1
25 Dexamethasone 2 2 2 1 1 1
26 Placebo 5 4 1 1 1 1
27 Dexamethasone 2 2 2 2 2 2
28 Dexamethasone 3 5 4 3 2 2
29 Placebo 3 2 1 1 1 1
30 Placebo 4 4 4 4 2 2
Patient Survey Ratings for Swelling  -  Raw Data
Swelling Ratings
Table  5
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Patient
Number Treatment 1 Day 2 Days 3 Days 4 Days 1 week Investigator
31 Placebo 4 6 6 4 2 2
32 Placebo 5 4 3 2 1 1
33 Placebo 2 2 2 1 1 1
34 Dexamethasone 3 4 4 4 1 1
35 Dexamethasone 3 4 4 3 1 1
36 Dexamethasone 4 4 4 4 1 1
37 Dexamethasone 2 4 4 3 2 1
38 Placebo 2 2 2 1 1 1
39 Dexamethasone 3 2 1 1 2 1
40 Placebo 6 6 6 5 2 1
41 Placebo 3 2 2 2 1 1
42 Dexamethasone 1 1 1 1 1 1
43 Dexamethasone 3 3 2 2 1 1
44 Placebo 2 2 1 1 1 1
45 Placebo 3 3 5 4 3 1
46 Placebo 5 4 2 1 1 2
47 Dexamethasone 1 3 4 2 1 1
48 Dexamethasone 3 2 1 1 1 1
49 Dexamethasone 4 3 2 2 1 1
50 Placebo 6 5 3 3 2 1
51 Dexamethasone 3 3 2 2 1 1
52 Dexamethasone 1 1 1 1 1 1
53 Placebo 2 2 2 1 1 1
54 Placebo 4 3 3 2 2 1
55 Placebo 3 3 3 3 1 2
56 Dexamethasone 2 2 2 3 5 5
57 Dexamethasone 4 3 2 1 1 1
58 Placebo 2 2 2 1 1 1
59 Dexamethasone 2 1 1 1 1 1
60 Placebo 2 2 2 1 1 1
Patient Survey Ratings for Swelling  -  Raw Data
Swelling Ratings
Table  5
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Average 
Rating Range
Standard 
Deviation
Dexamethasone :
Day 1  /  24 Hours 2.4 1 to 4 1.0
Day 2  /  48 Hours 2.6 1 to 5 1.1
Day 3  /  72 Hours 2.3 1 to 5 1.2
Day 4  /  96 Hours 1.8 1 to 4 0.9
1 week 1.3 1 to 5 0.8
Investigator's Rating at
1 week appointment 1.2 1 to 5 0.7
Placebo :
Day 1  /  24 Hours 3.1 1 to 6 1.5
Day 2  /  48 Hours 3.1 1 to 6 1.4
Day 3  /  72 Hours 2.5 1 to 6 1.3
Day 4  /  96 Hours 1.9 1 to 5 1.2
1 week 1.3 1 to 3 0.5
Investigator's Rating at
1 week appointment 1.2 1 to 3 0.5
General  Statistics  of  the Dexamethasone
and  Placebo  Group's  Swelling  Ratings
Table  6
69
Patient
Number Treatment 1 Day 2 Days 3 Days 4 Days 1 week Investigator
1 Dexamethasone 1 1 1 1 1 1
2 Placebo 1 1 1 1 1 1
3 Placebo 1 1 1 1 1 1
4 Dexamethasone 1 3 3 3 1.5 2
5 Dexamethasone 1 1 1 1 1 1
6 Placebo 1 1 1 1 1 1
7 Placebo 1 1 1 1 1 1
8 Dexamethasone 1 1 1 1 1 1
9 Dexamethasone 5 5 5 3 2 1
10 Placebo 1 1 1 1 1 1
11 Placebo 2 2 1 1 1 1
12 Dexamethasone 3 1 1 1 1 1
13 Dexamethasone 1 1 1 1 1 1
14 Placebo 4 4 3 3 2 1
15 Dexamethasone 1 1 1 1 1 1
16 Dexamethasone 1 2 2 1 1 1
17 Placebo 4 2 1 1 1 1
18 Placebo 2 2 2 2 1 1
19 Placebo 3 3 2 1 1 1
20 Placebo 1 1 1 2 1 1
21 Placebo 1 2 2 1 1 1
22 Dexamethasone 1 1 1 1 1 1
23 Dexamethasone 1 1 1 2 1 1
24 Dexamethasone 1 1 1 1 1 1
25 Dexamethasone 1 1 1 1 1 1
26 Placebo 1 1 1 1 1 1
27 Dexamethasone 3 2 2 2 1 1
28 Dexamethasone 1 3 4 4 3 3.5
29 Placebo 2 2 1 1 1 1
30 Placebo 3 3 2 2 1 1
Patient Survey Ratings for Bruising -  Raw Data
Bruising
Table  7
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Patient
Number Treatment 1 Day 2 Days 3 Days 4 Days 1 week Investigator
31 Placebo 4 5 3 2 2 1
32 Placebo 1 1 1 1 1 1
33 Placebo 1 1 1 1 1 1
34 Dexamethasone 1 1 1 1 1 1
35 Dexamethasone 1 2 4 4 2 3
36 Dexamethasone 1 1 1 1 1 1
37 Dexamethasone 1 5 5 5 3 3
38 Placebo 1 1 1 1 1 1
39 Dexamethasone 3 2 1 1 1 1
40 Placebo 6 6 6 5 1 1
41 Placebo 1 1 1 1 1 1
42 Dexamethasone 1 1 1 1 1 1
43 Dexamethasone 4 3 3 2 2 1
44 Placebo 1 1 1 1 1 1
45 Placebo 1 1 2 4 3 1
46 Placebo 1 1 2 2 1 1
47 Dexamethasone 1 1 1 1 1 1
48 Dexamethasone 1 1 1 1 1 1
49 Dexamethasone 5 5 4 3 3 2
50 Placebo 1 2 4 6 3 3
51 Dexamethasone 1 1 1 1 1 1
52 Dexamethasone 1 6 6 6 6 3
53 Placebo 2 2 2 1 1 1
54 Placebo 5 5 4 4 6 3
55 Placebo 3 3 1 2 2 2
56 Dexamethasone 1 2 2 1 2 3
57 Dexamethasone 5 4 3 3 2 2
58 Placebo 2 2 2 2 2 2
59 Dexamethasone 1 1 1 1 1 1
60 Placebo 1 1 1 1 1 1
Patient Survey Ratings for Bruising -  Raw Data
Bruising
Table  7
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Average 
Rating Range
Standard 
Deviation
Dexamethasone :
Day 1  /  24 Hours 1.7 1 to 5 1.3
Day 2  /  48 Hours 2.0 1 to 6 1.5
Day 3  /  72 Hours 2.0 1 to 6 1.5
Day 4  /  96 Hours 1.9 1 to 6 1.4
1 week 1.6 1 to 6 1.1
Investigator's Rating at
1 week appointment 1.5 1 to 3.5 0.8
Placebo :
Day 1  /  24 Hours 2.0 1 to 6 1.4
Day 2  /  48 Hours 2.0 1 to 6 1.4
Day 3  /  72 Hours 1.8 1 to 6 1.2
Day 4  /  96 Hours 1.8 1 to 6 1.3
1 week 1.4 1 to 6 1.0
Investigator's Rating at
1 week appointment 1.2 1 to 3 0.5
General  Statistics  of  the Dexamethasone
and  Placebo  Group's  Bruising  Ratings
Table  8
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Patient
Number Treatment 1 Day 2 Days 3 Days 4 Days 1 week Investigator
1 Dexamethasone 1 1 1 1 1 1
2 Placebo 2 1 1 1 1 2
3 Placebo 1 1 1 1 1 1
4 Dexamethasone 4 3.5 3 2.5 1.5 1
5 Dexamethasone 4 4 3 1 1 1
6 Placebo 1 1 1 1 1 1
7 Placebo 1 1 1 1 1 2
8 Dexamethasone 5 5 3 3 3 2
9 Dexamethasone 4 4 3 2 2 2
10 Placebo 2 2 2 2 2 2
11 Placebo 6 6 4 3 2 2
12 Dexamethasone 3 1 1 1 1 2
13 Dexamethasone 2 2 2 1 1 1
14 Placebo 5 4 3 3 2 1
15 Dexamethasone 3 3 1 1 1 2
16 Dexamethasone 1 1 1 1 1 1
17 Placebo 5 5 4 3 1 2
18 Placebo 3 2 2 2 1 1
19 Placebo 4 3 3 2 2 3
20 Placebo 5 4 4 2 1 2
21 Placebo 3 3 3 2 2 2
22 Dexamethasone 1 2 1 1 1 1
23 Dexamethasone 2 3 3 2 1 2
24 Dexamethasone 1 1 1 1 1 2
25 Dexamethasone 3 3 1 1 1 2
26 Placebo 2 1 1 1 1 2
27 Dexamethasone 3 2 2 2 1 1
28 Dexamethasone 3 4 4 3 3 3
29 Placebo 2 1 1 1 1 1.5
30 Placebo NR NR NR NR NR 2
Patient Survey Ratings for Intra-Oral Healing  -  Raw Data
Intra-Oral Healing Ratings
Table  9
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Patient
Number Treatment 1 Day 2 Days 3 Days 4 Days 1 week Investigator
31 Placebo 4 4 3 2 2 3
32 Placebo 4 3 3 2 2 2
33 Placebo 2 1 1 1 1 2
34 Dexamethasone 1 2 3 2 2 1
35 Dexamethasone 1 1 1 1 1 1
36 Dexamethasone 2 2 2 2 2 2
37 Dexamethasone 3 4 4 4 3 3
38 Placebo 4 3 2 1 1 2
39 Dexamethasone 3 2 1 1 1 2
40 Placebo 6 6 6 5 2 2
41 Placebo 4 4 4 2 2 3
42 Dexamethasone 1 1 1 1 1 1
43 Dexamethasone 4 4 3 2 1 3
44 Placebo NR NR NR NR NR 1
45 Placebo NR 2 3 4 4 2
46 Placebo 4 4 3 2 1 1
47 Dexamethasone NR NR NR NR NR 1
48 Dexamethasone NR NR NR NR NR 3
49 Dexamethasone NR NR NR NR NR 3
50 Placebo 3 3 3 3 2 3
51 Dexamethasone 3 3 3 2 1 1
52 Dexamethasone 5 5 5 5 5 3
53 Placebo 1 1 1 1 1 2
54 Placebo 6 6 4 3 3 3
55 Placebo NR NR NR NR NR 2
56 Dexamethasone 3 3 3 3 3 3
57 Dexamethasone NR NR NR NR NR 3
58 Placebo 2 2 2 2 2 2
59 Dexamethasone NR NR NR NR NR 2
60 Placebo NR NR NR NR NR 1
NR = No Rating
Patient Survey Ratings for Intra-Oral Healing  -  Raw Data
Intra-Oral Healing Ratings
Table  9
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Average 
Rating Range
Standard 
Deviation
Dexamethasone :
Day 1  /  24 Hours 2.6 1 to 5 1.3
Day 2  /  48 Hours 2.7 1 to 5 1.3
Day 3  /  72 Hours 2.2 1 to 5 1.2
Day 4  /  96 Hours 1.9 1 to 5 1.1
1 week 1.6 1 to 5 1.0
Investigator's Rating at
1 week appointment 1.9 1 to 3 0.8
Placebo :
Day 1  /  24 Hours 3.3 1 to 6 1.6
Day 2  /  48 Hours 2.8 1 to 6 1.7
Day 3  /  72 Hours 2.5 1 to 6 1.3
Day 4  /  96 Hours 2.0 1 to 5 1.0
1 week 1.6 1 to 4 0.7
Investigator's Rating at
1 week appointment 1.9 1 to 3 0.6
General  Statistics  of  the Dexamethasone
and  Placebo  Group's  Intra-Oral  Healing  Ratings
Table  10
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Figure 1: Inflammatory Cascade 
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 Figure 2: Inflammatory Cascade, NSAIDs and Corticosteroids 
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Figure 3:  Patient Survey 
 Date: Tooth Type: Investigator: Elena Kan, DDS Diagnosis:  Dear Participant:  As part of this research study, we require you to complete the chart below regarding your condition.  You are asked to examine and rate yourself in 4 categories– A through D (Pain, Swelling, Bruising and Healing) during the 4 days and on the day 7 following your surgery.  Each day (days 1-4 and day7), examine yourself and circle the appropriate rating number in each category.   Categories  A.   PAIN B.   SWELLING C.  BRUISING (DISCOLORATION) D.  INTRA-ORAL HEALING (WOUND HEALING) 24 hours  (1 Day)                            1    2     3    4    5    6 Any Medication?   Yes     No 
                           1    2     3    4    5    6                            1    2     3    4    5    6                            1    2     3    4    5    6 
48 hours  (2 Days)                            1    2     3    4    5    6 Any Medication?    Yes     No 
                           1    2     3    4    5    6                            1    2     3    4    5    6                            1    2     3    4    5    6 
72 hours  (3 Days)                            1    2     3    4    5    6 Any Medication?    Yes     No 
                           1    2     3    4    5    6                            1    2     3    4    5    6                            1    2     3    4    5    6 
96 hours  (4 Days)                            1    2     3    4    5    6                            1    2     3    4    5    6                            1    2     3    4    5    6                            1    2     3    4    5    6 168 hours  (1 Week)                            1    2     3    4    5    6                            1    2     3    4    5    6                            1    2     3    4    5    6                            1    2     3    4    5    6 
For Office Use and 
notation Only: 
If you experience significant pain you can take prescribed medication for first 3 days following surgery  Tylenol 500mg and Vicodin 5/300  Take both tablets together every 6 hours and record it in the chart. Donotexceed more than 4 doses in one 24 hour period 
       
Investigator (at 1 week appointment) 
                           1    2     3    4    5    6                            1    2     3    4    5    6                            1    2     3    4    5    6                            1    2     3    4    5    6   If you have any questions, please call Dr. Elena Kan at 704-689-4689.   Thank you for your participation. 
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 Figure 4: Chi-squared P Values 
 Values of the Chi-squared distribution 
 P 
DF 0.995 0.975 0.20 0.10 0.05 0.025 0.02 0.01 0.005 0.002 0.001 
1 0.0000393 0.000982 1.642 2.706 3.841 5.024 5.412 6.635 7.879 9.550 10.828 
2 0.0100 0.0506 3.219 4.605 5.991 7.378 7.824 9.210 10.597 12.429 13.816 
3 0.0717 0.216 4.642 6.251 7.815 9.348 9.837 11.345 12.838 14.796 16.266 
4 0.207 0.484 5.989 7.779 9.488 11.143 11.668 13.277 14.860 16.924 18.467 
5 0.412 0.831 7.289 9.236 11.070 12.833 13.388 15.086 16.750 18.907 20.515 
6 0.676 1.237 8.558 10.645 12.592 14.449 15.033 16.812 18.548 20.791 22.458 
7 0.989 1.690 9.803 12.017 14.067 16.013 16.622 18.475 20.278 22.601 24.322 
8 1.344 2.180 11.030 13.362 15.507 17.535 18.168 20.090 21.955 24.352 26.124 
9 1.735 2.700 12.242 14.684 16.919 19.023 19.679 21.666 23.589 26.056 27.877 
10 2.156 3.247 13.442 15.987 18.307 20.483 21.161 23.209 25.188 27.722 29.588 
11 2.603 3.816 14.631 17.275 19.675 21.920 22.618 24.725 26.757 29.354 31.264 
12 3.074 4.404 15.812 18.549 21.026 23.337 24.054 26.217 28.300 30.957 32.909 
13 3.565 5.009 16.985 19.812 22.362 24.736 25.472 27.688 29.819 32.535 34.528 
14 4.075 5.629 18.151 21.064 23.685 26.119 26.873 29.141 31.319 34.091 36.123 
15 4.601 6.262 19.311 22.307 24.996 27.488 28.259 30.578 32.801 35.628 37.697 
16 5.142 6.908 20.465 23.542 26.296 28.845 29.633 32.000 34.267 37.146 39.252 
17 5.697 7.564 21.615 24.769 27.587 30.191 30.995 33.409 35.718 38.648 40.790 
18 6.265 8.231 22.760 25.989 28.869 31.526 32.346 34.805 37.156 40.136 42.312 
19 6.844 8.907 23.900 27.204 30.144 32.852 33.687 36.191 38.582 41.610 43.820 
20 7.434 9.591 25.038 28.412 31.410 34.170 35.020 37.566 39.997 43.072 45.315 
21 8.034 10.283 26.171 29.615 32.671 35.479 36.343 38.932 41.401 44.522 46.797 
22 8.643 10.982 27.301 30.813 33.924 36.781 37.659 40.289 42.796 45.962 48.268 
23 9.260 11.689 28.429 32.007 35.172 38.076 38.968 41.638 44.181 47.391 49.728 
24 9.886 12.401 29.553 33.196 36.415 39.364 40.270 42.980 45.559 48.812 51.179 
25 10.520 13.120 30.675 34.382 37.652 40.646 41.566 44.314 46.928 50.223 52.620 
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Figure 5: 
 
Dexamethasone and Placebo Swelling Rating 
Frequency Distribution at 24 Hours 
 
 
 
Green = dexamethasone             Red = placebo 
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1 2 3 4 5 6
Rating 
Frequency
Rating 
80
Intra Oral Healing
Bruising
Swelling
Pain
Chi Squared 
Values .455                  2.706    3.841       5.412      6.635
P-Value .5                .1    .05        .02     .01
Figure 6:
Chi-Square Statistical Analysis Results of 
Recovery Components Ratings
at 24-hours in 2 x 2 Matrix of High and Low Ratings
(One Degrees of Freedom)
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